Sensus Healthcare to Report Fourth Quarter and Full Year 2025 Financial Results and Hold Business Update Conference Call on February 12, 2026

Sensus Healthcare, Inc. (Nasdaq: SRTS), a leading medical device company renowned for its non-invasive treatments for skin conditions, is set to announce its financial results for the fourth quarter and full year 2025 on February 12, 2026. The company's management will host a conference call at 4:30 p.m. Eastern Time to discuss the financial outcomes, update stakeholders on business developments, and answer participant questions.

Participants interested in joining the call can pre-register to receive an exclusive dial-in number and PIN, enabling them to bypass the live operator. The pre-registration link is available on the company's website, allowing users to register at any time, even post the call’s start time. For those who prefer not to pre-register, participation can still be achieved by calling either 844-481-2811 (U.S. and Canada) or 412-317-0676 (International). Listeners will be connected to the Sensus Healthcare conference call by the operator.

The call will also be available for live webcasting, providing another route for stakeholders to engage with the company’s updates. Following the conclusion of the conference, a telephone replay will be accessible until March 12, 2026, through specific dialing options and a designated replay code. Additionally, an archived webcast will be available on the company's Investor Relations webpage for a limited time.

As a pioneer in innovative treatments, Sensus Healthcare focuses on delivering solutions for skin cancer and keloids through advanced superficial radiotherapy technologies. The company’s commitment to enhancing patient care and advancing radiotherapy is evident in its patient-centric approach, aiming to provide safe and efficient treatment across various healthcare settings. For further details, visit www.sensushealthcare.com.

Sensus Healthcare, Inc. (Nasdaq: SRTS), a leading provider of non-invasive treatments for skin conditions, is set to report its fourth quarter and full-year financial results for 2025 on February 12, 2026. This upcoming earnings call presents significant insights into the company's performance and strategic direction, crucial for current and potential investors.

Investors should prepare for potential volatility in SRTS shares surrounding the earnings announcement. Analysts are keenly watching the company's revenue growth, profitability metrics, and forward guidance, particularly in a market increasingly focused on innovative healthcare solutions. Given Sensus' unique position in the healthcare sector, leveraging superficial radiotherapy technology, management's commentary will be vital in assessing the effectiveness of its product offerings amid evolving competition and regulatory landscapes.

It's important to analyze the context of Sensus' historical performance leading into this earnings report. Investors should consider past quarterly results, product developments, and market expansion efforts that may impact future performance. Key metrics to monitor include changes in revenue, gross margins, and operating expenses, as well as adoption rates of its SRT technology in clinical settings.

Furthermore, the conference call will offer insights into upcoming strategic initiatives and market conditions, which could impact Sensus’ stock price in the short and medium term. Engaging during the Q&A segment could provide investors with a clearer understanding of any challenges or opportunities the company might foresee.

In conclusion, investors are advised to approach SRTS with a considered outlook, analyzing key financial metrics and management guidance during the conference call. Staying informed of industry trends and the competitive landscape will also be essential in making educated investment decisions in Sensus Healthcare.